Tetraphse hikes on product launch

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares rose Friday after the company reported the commercial launch of XERAVA in the United States.

The Watertown, Mass.-based Tetraphase, a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the U.S. commercial launch of XERAVA™ (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).

The wholesale acquisition cost (WAC) of XERAVA will be $175 per day of therapy to support the Company’s strategy of having XERAVA used for the empiric treatment of cIAI.

Said CEO Guy Macdonald "The launch of XERAVA marks an important milestone for Tetraphase and for physicians with patients in need of a new broad-spectrum antibiotic for serious, often life-threatening, multidrug-resistant infections.

"This important achievement marks the culmination of many years of dedication and follows the regulatory approvals of XERAVA both by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency."

XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program.

In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated.

Shares moved up five cents, or 2.1%, to $2.44